Regeneron Pharmaceuticals REGN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's accounts payable?
- Regeneron Pharmaceuticals (REGN) reported accounts payable of $1.03B in Q1 2026.
- How has Regeneron Pharmaceuticals's accounts payable changed year-over-year?
- Regeneron Pharmaceuticals's accounts payable increased by 45.6% year-over-year, from $705.5M to $1.03B.
- What is the long-term trend for Regeneron Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's accounts payable has grown at a 14.6% compound annual growth rate (CAGR), from $475.5M to $939M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services received.
- How do you interpret accounts payable?
- An increase may suggest improved cash flow management or extended payment terms, while a decrease could indicate faster payments to suppliers or reduced purchasing activity.
- How does accounts payable compare across companies?
- Standard across all industries; peers in pharmaceuticals typically maintain consistent payable cycles aligned with procurement terms.